Aspirin Cuts Liver Fat in Preliminary MASLD Trial
(MedPage Today) -- Daily low-dose aspirin reduced hepatic fat in patients with noncirrhotic metabolic dysfunction-associated steatotic liver disease (MASLD), a randomized phase II trial showed.
Among the 80 patients in the single-center study...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news